Neumora Therapeutics, Inc.
NMRA$824M
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaWATERTOWN95 employees
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Feb 15, 2026
7dData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
2 upcoming, 0 past
⭐Phase 3Next
NMRA-335140 Phase 3 Results Expected
February 2026~NMRA-335140332
Primary completion for NMRA-335140 trial (NCT06058039) in Major Depressive Disorder
Source⭐Phase 3
NMRA-335140 Phase 3 Results Expected
May 2026~NMRA-335140332
Primary completion for NMRA-335140 trial (NCT06058013) in Major Depressive Disorder
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
NMRA-335140
Major Depressive Disorder
NMRA-335140 80 mg
Major Depressive Episode Associated With Bipolar II Disorder
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
NMRA-335140 | Phase 3 | Major Depressive Disorder | - |
NMRA-335140 80 mg | Phase 2 | Major Depressive Episode Associated With Bipolar II Disorder | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
NMRA News